PTCRA and pachyonychia congenita: In contrast, our signatures included specific mixtures of expression patterns that correlated with better DFS, i.e., RBPJ, RBPJL, ADAM17, ATNX1, and KAT2A, LFNG, HDAC2, SNW1, PSEN2 for patients below 55 years old at the early and late stages of PC, respectively; NOTCH3, APH1A, HDAC2, MFNG, DTX4 and HES5, ADAM17, CREBBP, DVL3, ADAM10 for patients 60–70 years old at the early and late stages of PC, respectively; finally, JAG1, PTCRA, HEYL, DTX3, RFNG for patients above 70 years old at the late stage of the disease (Figure 2, Table 3, Supplementary File S3).